HRP-anti-DXD-antibody is a conjugation product of HRP and anti-DXD-antibody. It can be used in PK, PD analysis and ELISA. Anti DXD;DXD抗体;单克隆DXD抗体;ACRO;百普赛斯;查看全部 公司简介百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业...
最新开发的 Anti-Dxd 抗体用于喜树碱衍生物Dxd偶联ADC的总抗体与偶联抗体浓度测定。 抗体偶联药物(Antibody-drug Conjugates,ADCs)主要由三部分组成:特异性靶向肿瘤的抗体、细胞毒性药物以及连接抗体和细胞毒性药物的连接子。ADCs解决了传统化疗药物靶向性差、对正常细胞毒性大的问题,提供了一种更加安全、靶向性更强的癌...
抗体药物偶联物(Antibody-drug conjugate, ADC)是一类用于治疗癌症的新兴靶向疗法,旨在将小分子化药(Payload)直接递送并杀伤肿瘤细胞,ADC本质上是一种靶向化疗药,已发展到第三代,安全性和有效性都大大提升,相应技术的革新更多的集中在Payload、Linker以及偶联...
来源 Monoclonal anti-DXD antibody, is produced from a hybridoma which was obtained from a mouse immunized with DXD.缓冲液 1×PBS, pH7.4.克隆类型 Monoclonal Antibody 亚型 IgG1宿主 Mouse 消光系数 1.4 浓度 1 mg/mL 纯度 >98% as determined by reduced SDS-PAGE >98% as determined by...
Anti-DXD antibody,mAb-biotin标记 抗DXD鼠单克隆抗体,生物素标记 编号:YKMP18020B/YKMP18021B 规格:25ul/100ul/1ml 应用:Elisa/WB Background Dxd (Exatecan derivative for ADC) is a potent DNA oisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ...
产品名称:Anti-Dxd Mouse IgG2a Antibody (17D6A4) 目录价:询价规格货号 GM-60248AB-100 100μg GM-60248AB-1000 1mg产品简介 Expression System CHO Aggregation < 5% as determined by SEC-HPLC Purity >95% as determined by SDS-PAGE Endotoxin <1 EU/mg by LAL Sterility 0.2 μm Filtered Target DXD...
2. 活性(Bioactivity)- ELISA Mouse Anti-Dxd antibody,ELISA 4 3 Antibody ADC(Antibody-Dxd)(Dar8) 2 1 0 0.00001 0.0001 0.001 0.01 Conc.(ug/ml) EC50=0.012ug/ml 0.1 1 Anti-DXD mIgG2a 抗体与某一 ADC 分子的结合曲线,EC50=0.012 ug/ml. 说明 1. anti-Dxd 抗体有多个克隆株可以提供,便于筛选...
Antibody–drug conjugate (ADC)trastuzumab deruxtecanDS-8201aDXdpharmacokineticsbiodistributionmetabolismxenograftdrug delivery system (DDS)Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate (ADC), comprising an anti-HER2 antibody (Ab) at a drug-to-Ab ratio of 7鈥 8 with the...
抗体药物偶联物(Antibody-drug conjugate, ADC)是一类用于治疗癌症的新兴靶向疗法,旨在将小分子化药(Payload)直接递送并杀伤肿瘤细胞,ADC本质上是一种靶向化疗药,已发展到第三代,安全性和有效性都大大提升,相应技术的革新更多的集中在Payload、Linker以及偶联技术等环节,针对Payload的改造与更新也一直是ADC优化的重点方...
抗体药物偶联物(Antibody-drug conjugate, ADC)是一类用于治疗癌症的新兴靶向疗法,旨在将小分子化药(Payload)直接递送并杀伤肿瘤细胞,ADC本质上是一种靶向化疗药,已发展到第三代,安全性和有效性都大大提升,相应技术的革新更多的集中在Payload、Linker以及偶联技术等环节,针对Payload的改造与更新也一直是ADC优化的重点方...